Bamco Inc. NY decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,798,041 shares of the company’s stock after selling 86,088 shares during the quarter. IDEXX Laboratories accounts for approximately 3.3% of Bamco Inc. NY’s holdings, making the stock its 5th biggest position. Bamco Inc. NY owned approximately 2.25% of IDEXX Laboratories worth $1,216,429,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at $3,666,459,000. State Street Corp grew its holdings in shares of IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after buying an additional 138,956 shares in the last quarter. J. Stern & Co. LLP grew its holdings in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on IDXX. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $751.00.
IDEXX Laboratories Stock Performance
Shares of NASDAQ IDXX opened at $546.09 on Thursday. The business’s 50-day moving average price is $562.51 and its two-hundred day moving average price is $622.66. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The company has a market capitalization of $43.08 billion, a P/E ratio of 40.21, a price-to-earnings-growth ratio of 3.13 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
